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Summary  
Platelet activation at sites of vascular injury leads to the formation of a 
hemostatic plug and is crucial for hemostasis. However, uncontrolled platelet 
activation may lead to the formation of occlusive thrombi. Several soluble or 
matricellular proteins can activate platelets. In this article we review recent 
advances on the role of galectins in platelet physiology.  Either in soluble or 
immobilized form, these endogenous glycan-binding proteins trigger platelet 
activation through modulation of discrete signaling pathways. We discuss the role 
of platelet-galectin interactions not only in hemostasis, but also in chronic 
inflammation, atherosclerosis and cancer. 
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 Platelets 
 
Platelets are anucleated cell fragments released from megakaryocytes. The 
primary role of platelets is to initiate and maintain haemostasis. However, their 
function is not limited to thrombosis, and extends into physiological processes such 
as tissue repair, wound remodeling and antimicrobial host defense, or pathologic 
processes such as atherosclerosis, chronic inflammation or cancer (Wagner 2005; 
Rivera, Lozano et al. 2009; Leslie 2010). In all these processes, platelets act as 
sentinels capable of responding rapidly to chemical changes in their environment.  
Under physiological conditions, platelets circulate in the blood in a quiescent state 
and their activation is inhibited by both, nitric oxide and prostacyclin released from 
endothelial cells. However, after vascular injury, platelets become activated and 
provide rapid protection against bleeding and catalyze the slower formation of 
stable blood clots via the coagulation cascade. In the initiation phase of primary 
hemostasis, platelets roll, adhere, and spread on the collagen matrix to form an 
activated platelet monolayer. During the rolling phase, adhesion is mediated mainly 
by the interaction between the glycoprotein (GP) Ib/V/IX receptor complex on the 
platelet surface with von Willebrand Factor (vWF), and between the GPVI and 
integrin IaIIa proteins with collagen present in the exposed subendothelium. These 
interactions allow the arrest and activation of adherent platelets. Platelet adhesion 
triggers the release of soluble mediators such as adenosine 5-diphosphate (ADP), 
thromboxane A2 (TXA2) and serotonin, which in combination with the locally 
generated thrombin, allow the formation of platelet-platelet aggregates and the 
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recruitment of additional circulating platelets which extend and stabilize the 
hemostatic plug. Specific interactions of these agonists with their G-protein coupled 
receptors generate inside-out signaling leading to the conformational activation of 
integrins, in particular Ib3, increasing their ligand affinity (Angiolillo, Ueno et al. 
2010). Binding of Ib3 to its ligands, mainly fibrinogen, supports processes such 
as clot retraction, platelet aggregation and secretion of the granule proteins (Ma, 
Qin et al. 2007; Rivera, Lozano et al. 2009). Platelets contain four types of storage 
compartments –α-granules, dense granules, peroxisomes and lysosomes – whose 
contents are released into the circulation. When stimulated by thrombin, the 
platelet releasate contains > 300 proteins including prothrombotic substances, 
growth factors, chemokines and proteases. Although the release of cargo during 
exocytosis delivers many proteins into the circulation, the process also alters the 
composition of the platelet membrane, resulting in surface expression of P-selectin 
and an increase in the number of integrin IIb3 molecules (Nurden, Nurden et al. 
2008). The exposure of P-selectin is especially important for platelet–leukocyte and 
platelet-endothelial interactions, as this molecule mediates the initial interactions of 
leukocytes and endothelium with activated platelets (Wagner 2005).  
The ability of platelets to store and release such a variety of bioactive 
mediators allows them to play an important role in modulating the function of other 
cells and explains why platelets are also critically involved in other biological 
processes beyond hemostasis. 
 
Galectins 
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Galectins are evolutionarily-conserved lectins defined by at least one carbohydrate 
recognition domain (CRD) with affinity for β-galactosides and conserved sequence 
motifs. These lectins are found in almost all organisms and to date 15 galectins 
have been found in mammals; although only 12 galectin genes are found in 
humans. On the basis of their molecular structure, galectins are classified into 
three main types: ‘proto-type’ galectins, comprising a single polypeptide chain that 
is able to dimerize (galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15); “tandem 
repeat-type” galectins, composed of a single polypeptide chain presenting two 
CRDs connected by a linker peptide (galectin-4, -6, -8, -9, and -12); and the 
“chimera-type” galectin-3, which consists of one C-terminal CRD linked to an N-
terminal peptide. A more recent classification based on gene sequence 
comparisons and intron–exon position analysis has classified galectins’ CRDs into 
two distinct subgroups (F3 and F4). Peculiarly, bi-CRD galectins usually display 
one domain of each type, F3 and F4 (Di Lella, Sundblad et al. 2011).  Although 
most galectins bind N-acetyllactosamine [Galβ1–4-NAcGlc] units, important 
differences in glycan binding preferences among different members of the family 
have been reported (Rabinovich and Toscano 2009). Galectins function, either 
intracellularly or extracellularly, as key biological mediators capable of monitoring 
changes occurring on the cell surface during fundamental biological processes 
such as cellular communication, inflammation, wound healing, development, and 
differentiation. They also play unique roles in intracellular signaling pathways, 
regulation of RNA splicing, cell cycle control, and control of apoptotic signaling, 
endocytosis machinery, and trafficking (Di Lella, Sundblad et al. 2011).  Galectins 
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can influence the capacity of innate immune cells (e.g., neutrophils, dendritic cells, 
monocytes/macrophages, eosinophils, and mast cells) to respond to chemotactic 
gradients, migrate across endothelial cell surfaces, synthesize and release both 
pro- and anti-inflammatory mediators, and recognize, engulf, and kill microbes and 
damaged cells.  In this regard, similar to alarmins some members of the galectin 
family contribute to trigger innate immune responses, while others influence the 
resolution of acute inflammation. Besides, galectins can bind glycans on the 
surface of pathogenic microbes coupling recognition processes to innate immunity 
(Davicino, Elicabe et al. 2011). 
 In spite of lack of a typical leader peptide required for secretion, galectins are 
released onto the extracellular milieu through an unusual, mostly unresolved 
mechanisms, where they play key roles as soluble mediators of various cell 
functions. In fact, galectins have been proposed to exert biological activities by 
forming supramolecular structures, termed “lattices” with cell surface N-and O-
glycans (Rabinovich, Toscano et al. 2007) 
Most galectins are expressed in a wide variety of tissues. While some 
galectins (e.g., galectin-1 and -3) are widely expressed among different tissues of 
various species, other family members have a more restricted tissue localization 
and compartmentalization (e.g., galectin-7 is preferentially found in the skin, 
galectin-12 abundantly expressed in adipose tissue, galectin-5 restricted to rat 
reticulocytes, and galectin-10 strongly represented in human eosinophils, where 
they play essential roles in the control of cell fate (Di Lella, Sundblad et al. 2011). 
Most galectins are overexpressed in several types of tumors and their expression 
correlates with tumor progression, aggressiveness and metastatic phenotype (Liu 
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and Rabinovich 2005). For example, galectin-1 overexpression contributes to 
tumor immune escape, modulates tumor cell migration and adhesion and 
influences tumor angiogenesis (Thijssen, Postel et al. 2006). High expression of 
galectin-8 is associated with malignancy in some type of tumors such as colon and 
lung and, preliminary studies showed that inhibition of galectin-8 promotes tumor 
regression (Bidon-Wagner and Le Pennec 2004).  
 
Platelet Activation Responses Induced by Galectin- 1 and -8 
 
Hemostasis and pathological thrombus formation are dynamic processes that 
require a co-ordinated series of events involving platelet membrane receptors, 
bidirectional intracellular signals, and release of platelet proteins and inflammatory 
substances. Platelet activation can be triggered by a broad spectrum of vascular 
adhesive proteins such as vWF, collagen, fibronectin and soluble agonists 
including ADP, TXA2, thrombin and serotonin. (Rivera, Lozano et al. 2009).  It has 
been recently shown that two structurally different members of the galectin family 
of proteins, galectin-1 and 8 are potent platelet agonists (Pacienza, Pozner et al. 
2008; Romaniuk, Tribulatti et al. 2010; Romaniuk, Croci et al. 2012). Through the 
interaction with the carbohydrate backbone of the major platelet receptors involved 
in hemostasis, e.g.: GPIbVIX complex and integrin IIbβ3, both galectins are 
capable to induce all the myriad of platelet responses including adhesion and 
spreading, aggregation, release of their granule content and the expression of P-
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selectin on the platelet membrane (Pacienza, Pozner et al. 2008; Romaniuk, 
Tribulatti et al. 2010; Romaniuk, Croci et al. 2012).  
 
Platelet receptors for Galectin-1 and Galectin 8 
 
Most of the extracellular functions mediated by galectins involve the interaction of 
these proteins with different cell surface glycoconjugates containing repeating units 
of N-acetyllactosamine [Galβ1,4GlcNAc] as well as extracellular matrix proteins . 
Among the different receptors, integrins are known to be involved in galectin-
mediated biological responses (Rabinovich, Toscano et al. 2007). Platelet 
activation mediated by galectin-1 or galectin-8 is prevented by lactose but not by 
sucrose indicating the interaction of these lectins with specific carbohydrate ligands 
on the platelet surface. MALDI/TOF mass spectrometry analyses determined that 
both galectins binds the subunit IIb from the IIbβ3 integrin (Pacienza, Pozner et 
al. 2008; Romaniuk, Tribulatti et al. 2010). Additionally, while galectin-8 also binds 
GPIb and V from GPIb-IX-V complex (Romaniuk, Tribulatti et al. 2010), galectin-1 
interacts with β1. However, the use of platelets derived from patients who are 
deficient in IIbβ3 or in GPIb, revealed that only GPIb and integrin IIbβ3 are 
essential for galectin-8- and 1 dependent signal transduction respectively, and 
therefore represent functional counter-receptors (Romaniuk, Tribulatti et al. 2010; 
Romaniuk, Croci et al. 2012).  
Similar to other integrins, the function of platelet αIIbβ3 is regulated by inside-out or 
outside-in signaling. Inside-out signaling occurs in response to binding of one or 
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more platelet agonists and leads to the conversion of αIIbβ3 from a low-
affinity/avidity receptor to a high-affinity/avidity receptor, thereby allowing 
engagement of soluble multivalent adhesive ligands, such as fibrinogen and vWF. 
Ligand binding to the integrin triggers another cascade of signals known as 
outside-in, which leads to irreversible adhesion and aggregation (Ma, Qin et al. 
2007). In this context, galectin-1 acts as a peculiar agonist as it is capable of 
triggering platelet activation through outside-in signaling via direct binding to αIIbβ3 
integrin. This intrinsic property of galectin-1 may be associated to a general feature 
of galectins, which has been proposed to form ordered arrays of supramolecular 
structures composed of multivalent glycans and lectins (often termed “lattices”) on 
the cell surface (Yang, Rabinovich et al. 2008). Thus, it is conceivable that 
galectin-1 binding to αIIbβ3 integrin forms lattices that induce integrin clustering 
that leads to platelet signaling and activation.  
 
Signaling Pathways involved in galectin-mediated platelet activation 
Although the model of how GPIb–GPIX–GPV signals in human platelets is 
currently incomplete, the activation of Src, PI3K, PLCγ 2 and ERK appears to be 
involved in GPIb activation mediated by vWF binding, its major ligand (Ozaki, 
Asazuma et al. 2005). In accordance with the notion that GPIb is an essential 
receptor for transducing galectin-8 signaling, platelet stimulation by galectin-8 
results in phosphorylation of PLCγ2, ERK1/2 and Akt. The phosphorylation of 
PLCγ2 and Akt appear to be relevant for platelet activation induced by galectin-8 
since platelet aggregation is impaired in the presence of specific inhibitors of PLC 
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and PI3K but not of MAPKK (Romaniuk, Tribulatti et al. 2010). 
Downstream signals involved in galectin-1 binding to platelets include the 
most common signals elicited by soluble or adhesive agonists that induce 
activation of αIIbβ3 integrin, such as Ca
2+ mobilization and phosphorylation of PLCγ, 
Syk, mitogen-activated protein kinases (MAPKs), Akt, and β3 integrin. Tyrosine 
phosphorylation of the integrin tyrosine cytoplasmic motif of the β3 subunit is one of 
the most proximal and specific signaling events occurring after ligand binding to 
αIIbβ3 integrin and it is evident in vitro only under stirring conditions that allow 
integrin clustering or on platelet adhesion to immobilized fibrinogen (Ma, Qin et al. 
2007). Galectin-1-induced phosphorylation of β3 integrin occurs rapidly in addition 
of galectin-1 to platelet suspensions. Moreover, rapid tyrosine phosphorylation of 
Syk, PLCγ2, and Akt (signaling events involved in platelet outside-in signaling) was 
also observed after platelet exposure to soluble galectin-1 (Romaniuk, Croci et al. 
2012). Interestingly, phosphorylation of these kinases has been described on 
platelet stimulation with concanavalin A, a plant lectin with different glycan 
specificity but similar conformation and topology that triggers platelet activation by 
inducing clustering of αIIbβ3 integrin molecules (Torti, Festetics et al. 1999). 
 
Galectin-1 and galectin-8 trigger platelet aggregation  
 
The capacity of platelets to form a thrombus depends on their ability to aggregate. 
At the molecular level, platelet aggregation is mediated by a specific receptor on 
the platelet surface: the αIIbβ3 integrin (Rivera, Lozano et al. 2009). Like most 
traditional platelet agonists, both soluble galectin-1 and galectin-8 promote the 
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transition of this integrin from a low-affinity state (resting state) to a high-affinity 
state (active state), which results in the unmasking of neoepitopes in the αIIbβ3 
complex, and allows fibrinogen binding which acts as a bridging molecule between 
platelets to form aggregates. This conformational change of αIIbβ3 integrin 
triggered by galectins is accompanied by a raise in intracellular calcium levels as 
well as morphological changes of platelets involving the rearrangement of the 
cytoskeleton including extension of filopodia and lamellipodia (spreading) and F-
actin polymerization (Pacienza, Pozner et al. 2008; Romaniuk, Tribulatti et al. 
2010).  
Both, galectin-1 and galectin-8 induce aggregation of platelets suspended 
either in plasma or buffer, which indicates a relevant role of these lectins in 
physiological media. Although cell agglutination was one of the first biological 
activities described for these lectins, this effect on platelets was only observed at 
high galectin-1 and galectin-8 concentrations. Platelet aggregation at lower 
concentrations is absent in fixed platelets, in the presence of calcium chelating 
agents, or eptifibatide (an αIIbβ3 antagonist), implying that platelet responses 
mediated by galectins could be related either to cell activation or to a clustering 
effect of platelet surface receptors depending on their concentration (Pacienza, 
Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). Although both galectins were 
capable of promoting aggregation, galectin-8 was found to be ten times more 
potent than galectin-1 in this stimulatory effect. Although the dimeric structure of 
galectin-8 would anticipate a more robust effect of this galectin compared to 
galectin-1, the observation that only the N-terminal domain was also able to trigger 
platelet activation indicates that lectin bivalency is not essential to promote 
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activating effects on platelets. The differences in the concentration required to 
achieve a similar effect, could therefore reflect different downstream molecular 
signals triggered by each galectins (Romaniuk, Tribulatti et al. 2010; Romaniuk, 
Negrotto et al. 2011).  
The initial formation of platelet thrombus is rapidly reinforced by the 
generation and release of platelet TXA2 and ADP (the main metabolite of 
arachidonic acid by the cyclooxigenase pathway, and a component of platelet 
dense granules respectively) which acting in a paracrine and autocrine manner 
promote further platelet activation (Rivera, Lozano et al. 2009). Both molecules are 
generated on platelet stimulation by galectin-1 and -8 (Pacienza, Pozner et al. 
2008; Romaniuk, Tribulatti et al. 2010). Moreover, although the aggregation 
response triggered by low galectin-8 concentrations was inhibited in the presence 
of aspirin (cyclooxigenase inhibitor) and/or an ADP-scavenger, a full response was 
obtained at higher concentrations indicating that galectin-8 is a strong agonist that 
activate platelets independently from TXA2 formation or ADP release (Pacienza, 
Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). 
 
Proinflammatory and procoagulant platelet-mediated responses induced by 
galectins 
 
The role of platelets in inflammation and vascular repair is mainly associated to the 
release of their alpha granule content, which includes among others, cell adhesion 
molecules that favor platelet/endothelial and leukocyte interaction, prothrombotic 
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substances, and angiogenesis regulatory growth factors (May, Seizer et al. 2008; 
Etulain J 2012).  
Galectin-1 and -8 are strong inducers of P-selectin expression (Pacienza, 
Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). The major role of P-selectin 
on the platelet surface is the interaction with PSGL-1, its major counter-receptor on 
leukocytes, to form platelet-leukocyte aggregates (Wagner 2005). In fact, activation 
of platelets by galectin-1 in the presence of polymorphonuclear leukocytes results 
in a significant formation of heterotypic cell aggregates (Pacienza, Pozner et al. 
2008). This interaction promotes activation of both cell types, which is a crucial 
condition for triggering inflammation, vascular remodeling and thrombosis. The 
expression of P-selectin on the platelet surface, the formation of leukocyte-platelets 
aggregates and leukocyte activation, are relevant events in acute syndromes 
including coronary diseases as well as in deep vein thrombosis (DVT) (Dotsenko, 
Chaturvedi et al. 2007; Etulain J 2012), Given that galectins promote all these 
responses, binding of these lectins to platelets might represent potentially novel 
mechanism involved in both, arterial and venous thrombosis.  
In a cancer setting, the formation of heterotypic aggregates between 
circulating tumor cells overexpressing galectin-1 or -8 and platelets would result in 
P-selectin expression, which may contribute to the metastatic properties of these 
galectins by promoting stable adhesion to the endothelium and/or transmigration of 
tumor cells outside of the vasculature. 
vWF is a large multimeric glycoprotein that allows platelet-endothelium, 
platelet-subendothelium and platelet-platelet interaction and is therefore important 
for platelet adhesion and thrombus formation. Similarly to P-selectin, vWF is stored 
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in platelet -granules and in Weibel-Palade bodies of endothelial cells from which 
is released during injury or inflammation. vWF is a biomarker for endothelial 
dysfunction and cardiovascular risk and high levels of vWF are found in both 
chronic and acute inflammation (Luo, Ni et al. 2012). The release of vWF occurs 
after activation of platelets by galectin-1 (unpublished data) and -8 (Romaniuk, 
Tribulatti et al. 2010). Thus, P-selectin expression and vWF release mediated by 
galectins might play an important role in the pathogenesis of thrombus formation 
and the modulation of inflammatory responses. 
While galectin-8 has been linked to proinflammatory processes (Cattaneo, 
Tribulatti et al. 2011), both, anti and proinflammatory activities have been 
described for galectin-1 (Liu and Rabinovich 2010). Whether anti-inflammatory and 
pro-inflammatory effects occur at different concentrations of galectin-1 still remains 
to be established. The fact that galectin-1 promotes platelet activation support to 
the notion that under certain circumstances, galectin-1 could also act as a pro-
inflammatory factor.  
Vesiculation of the platelet membrane and formation of platelet 
microparticles (PMPs) is a characteristic effect of certain agonists such as 
collagen, thrombin or C5b-9 complement fragment. PMPs are released not only 
during platelet activation in vitro but are also detected in vivo (Morel, Toti et al. 
2006). They are thought to provide catalytic surface for several enzyme complexes 
of the coagulation system and to underlie the pro-coagulant responses elicited by 
platelet activation. Moreover, PMPs may themselves evoke cellular responses in 
the immediate microenvironment including platelet adhesion to the site of 
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endothelial injury and angiogenesis. The ability of galectin-1  to induce 
phosphatidylserine-expressing PMPs (Pacienza, Pozner et al. 2008) suggests that 
this lectin not only promotes platelet activation, but could also indirectly activates 
the coagulation cascade.   
 
Galectins and platelet adhesion  
 
Platelet adhesion and spreading, together with cytoskeletal rearrangements, are 
early functional responses that occur upon vascular injury as a consequence of 
outside-in signaling on ligand binding to αIIbβ3 and integrin oligomerization (Rivera, 
Lozano et al. 2009). Platelet adhesion to the extracellular matrix at sites of vascular 
injury represents a key step for limiting bleeding but, if uncontrolled, can lead to 
occlusion. Immobilized galectin-1 and -8 are efficient substrates for platelet 
adhesion, filopodia, and lamellipodia formation in the absence of additional platelet 
agonists (Pacienza, Pozner et al. 2008; Romaniuk, Croci et al. 2012). The 
demonstration that immobilized galectins are as efficient as their soluble form in 
triggering platelet activation together with the observation that their expression is 
increased in activated endothelium or tumor cells (Thijssen, Hulsmans et al. 2008), 
suggest that the interaction of platelets with immobilized galectin-1 or -8 could be 
relevant in different clinical settings, including not only vascular but also 
inflammatory disorders such as atherosclerosis and cancer. Several studies 
demonstrated that galectins including galectin-1 and -8 participate in the initiation, 
progression and rupture of an atheroma plaque (Al-Ansari, Zeebregts et al. 2009). 
Galectins expressed in the inner of atheroma plaque, may not only influence 
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platelet activation but may also serve as key components of the extremely 
thrombogenic core exposed after plaque rupture, the main trigger for acute 
thrombus formation and the cause of unstable angina, myocardial infarction, 
transient ischemic attack and stroke (May, Seizer et al. 2008).  
In cancer, platelets are known to contribute to tumor progression and 
metastasis. One of the mechanisms underlying this effect is the formation of 
mixed-cell aggregates between tumor cells expressing mucins and platelets 
expressing P-selectin; these complexes prevent tumor cell attack by the immune 
system (Leslie 2010). In the same line of evidence, the interaction between tumor 
cells expressing high levels of galectins and platelets could represent another 
molecular mechanism through which both, platelets and galectins promote the 
metastatic cascade. Interestingly and in contrast to mucin-P-selectin interactions, 
the interaction of tumor cells with platelets via galectins would not require the 
presence of activated platelets. Furthermore, the overexpression of galectins in 
tumor cells could also represent a trigger for platelet activation allowing the release 
of -granules content including growth factors, which can promote tumor 
progression and angiogenesis. 
 
Platelets express galectin-1 and galectin-8 
 
In addition to vascular cells, human platelets express substantial levels of galectin-
1 and -8 (Pacienza, Pozner et al. 2008; Romaniuk, Tribulatti et al. 2010). Although 
both galectins are secreted proteins, they are mainly found in the cytosol of 
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different cell types. Human platelets express the two splice variants of galectin-8. 
Moreover, whereas galectin-8, like P-selectin, is absent on the surface of resting 
platelets, it is exposed on the membrane of thrombin-stimulated platelets 
(Romaniuk, Tribulatti et al. 2010). This finding suggests that in the vascular 
system, platelets are another source of galectin-8 that would be accessible upon 
platelet activation to eventually promote thrombus growth. Furthermore, it has been 
recently shown that galectin-8 regulates platelet function by mediating the uptake 
of platelet proteins (i.e. FV) by megakaryocytes (Zappelli, van der Zwaan et al. 
2012). In contrast, galectin-1 is not expressed on the platelet surface upon 
activation (unpublished observations). The differences between both galectins are 
still not clear. Interestingly, addition of lactose and thiodigalactoside partially 
prevents aggregation induced by classical agonists suggesting that platelet-derived 
galectins and their glycans might contribute to platelet activation.  
Thrombosis and disseminated intravascular coagulation are common 
complications in cancer patients. A hypercoagulable or pro-thrombotic state of 
malignancy occurs due to the ability of tumor cells to activate platelets and the 
coagulation system. Pro-thrombotic factors in cancer include the ability of tumor 
cells to produce and secrete pro-coagulant/fibrinolitic substances and pro-
inflammatory cytokines and the physical interaction between tumor cells and 
platelets. However, the mechanisms allowing the occurrence of prothrombotic 
states in cancer patients are not completely understood.  
The observed increased of galectin-1 and -8 in tumoral endothelial cells as 
well as in other malignant cells could represent a pathogenic mechanism involved 
in thrombosis and disseminated intravascular coagulation complications. Given the 
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pivotal role of galectin-1 and -8 in tumor progression, it could be conceivable that 
galectin-induced platelet activation might contribute to the pathogenesis of 
thrombosis in cancer patients 
 
Galectin-1 plays a role in normal primary hemostasis 
 
The relevance of galectin-1 in hemostasis, has been recently studied in galectin-1 
null mutant mice. Animals deficient in galectin-1 had prolonged bleeding time, an 
effect which was not associated with a decrease in platelet number but rather to a 
platelet dysfunction. In fact, galectin-1-deficient platelets showed a restricted 
adhesion to immobilized fibrinogen and a delayed clot retraction, two platelet 
activation responses dependent on outside-in signaling of platelet integrin αIIbβ3 
(Romaniuk, Croci et al. 2012). Thus, an impairment of this activation pathway 
appears to be a major cause of the altered bleeding time in mice lacking galectin-1. 
Interestingly, many of the hemostatic alterations present in mice with galectin-1 
ablation recapitulate the phenotypes observed in mice devoid of the tetraspanin 
superfamily member TSSC6 or in mice in which the integrin cytoplasmic tyrosine 
motif has been mutated to phenylalanine, which all exhibited impaired outside-in 
signaling (Romaniuk, Croci et al. 2012). The concept that galectin-1 has a role 
in hemostasis was also recently described by Saint-Lu N et al. who showed 
that galectin-1/galectin-3 double-deficient mice are characterized by a more 
rapid formation of initial thrombi following ferric chloride–induced injury, but 
occlusive thrombi less stable compared with those of wild-type mice(Saint-
Lu, Oortwijn et al. 2012). 
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Conclusions 
Over the last decade we have witnessed significant advances regarding the 
biology of galectins and their role in cellular homeostasis: Particularly considerable 
progress has been made on the contribution of galectins to innate and adaptive 
immune responses.The information currently available indicates that galectins are 
expressed and secreted by several cell types in normal and pathologic 
conditions.The emerging evidence showing that galectins are also capable of 
triggering platelet activation opens a completely new field of research where so far 
there are more questions than answers. From a more general perspective, this 
field will also uncover the role of glycans and glycosyltransferases in platelet 
function and hemostasis. The study of galectin-glycan interactions in platelet 
activation will provide further insight into the mechanisms linking inflammatory 
mediators to thrombus formation and could expand our view of the role of platelets 
much beyond homeostasis to their pathophysiologic role during inflammation and 
cancer. 
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